ŞÇŞeyma Çalık

Şeyma Çalık

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Şeyma Çalık has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brucella Epididymoorchitis: 10 Years of Experience in a Single Center with 42 Cases

    by Mustafa Arslan, Seyma Calık

    Objective: We aimed to describe the clinical, epidemiological, and laboratory characteristics of patients with Brucella epididymoorchitis (BEO) and reveal the effectiveness of the treatment options and recurrence rates after treatment. Methods: The information of 42 BEO patients who were followed and treated in a tertiary training and research hospital between January 2013 and January 2023 was accessed by scanning the patient files retrospectively. Epididymoorchitis diagnosis was based on physical examination findings (testicular swelling, pain, rash) and/or by ultrasonography in patients with a standard tube agglutination test (STA) ≥1/160 and a positive rose-Bengal (RB) test or Brucella bacteria growth in blood cultures. Results: Forty-two patients with brucellosis-associated epididymoorchitis were included in the study. STA>1/160, and RB tests were positive in all patients. While the incidence of BEO among all patients was 10.9%, the incidence of BEO among male patients was 16.1%. The rate of unilateral testicular involvement in the patients was 92.86%, and the rate of bilateral testicular involvement was 7.14%. Pain accompanied testicular growth in 66.6% of the patients. Most patients (76.19%) were detected during the acute brucellosis period. Doxycycline (DOK) and rifampicin (RIF) combination was given to 13 patients, DOK and streptomycin (SM) combination to 22 patients, DOK and gentamicin (GEN) combination to 5 patients, and DOK, RIF and SM combination to two patients. The relapse rate was 4.76% in the patient group treated with DOK and RIF; relapse was not observed in the group of patients treated with DOK and aminoglycoside (SM or GEN). Conclusion: BEO is a complication of brucellosis. It can be treated successfully through early diagnosis, appropriate antimicrobial treatment for six weeks, and practices that increase patient compliance with treatment. Treatment combinations containing aminoglycosides are statistically superior in preventing relapses than combinations containing RIF.

  • Carbapenem-resistant Klebsiella pneumoniae outbreak with monoclonal spread: Evaluation of resistance genes and ceftazidime-avibactam susceptibility

    by Neslihan Arıcı, Elif Seren Tanrıverdi, Şeyma Çalık, Nilgün Kansak, Rıza Adaleti, Barış Otlu, Sebahat Aksaray


  • Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli

    by Rıza Adaleti, Yaşar Nakipoğlu, Neslihan Arıcı, Nilgün Kansak, Şeyma Çalık, Seniha Şenbayrak, Recep Balık, Sebahat Aksaray

    The rate of extensively drug-resistant and pan-resistant gram-negative rods isolated as infectious agents is increasing around the world and in Turkiye. One of the important options in the treatment of these infections is the combined use of antibiotics. Therefore, the aim of this study was to investigate the in vitro effect of meropenem/colistin and meropenem/fosfomycin combinations on carbapenem-resistant gram-negative bacilli isolated as infectious agents. Escherichia coli (n= 6), Klebsiella pneumoniae (n= 10), Pseudomonas aeruginosa (n= 5), and Acinetobacter baumannii (n= 6) isolates were recovered from blood and tracheal aspirate samples of patients hospitalized in our hospital's intensive care unit were included in the study. In the first stage of the combination study, minimal inhibitory concentrations (MIC) were investigated by broth microdilution for meropenem and colistin, and agar dilution methods for fosfomycin. In the second stage of the study, synergy, partial synergy, indifference, and antagonistic effects were investigated with the checkerboard method for the meropenem/colistin combination and the agar dilution method for the meropenem/fosfomycin combination. The checkerboard results were interpreted as follows: fractional inhibitory concentration index (FICI) values <= 0.5 synergy, < 0.5-<= 1 partial synergy, > 1-<= 4 indifference and FIC values of > 4 antagonism. MIC values obtained in the study were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Of the 27 isolates studied with the broth microdilution method, 63% were found to be colistin-resistant and 37% susceptible. The MIC values of fosfomycin against Enterobacterales group bacteria were found to be in the range of 2-2048 mg/L. Two of the six E.coli isolates and nine of the 10 K.pneumoniae isolates were found to be resistant to fosfomycin (IV). The MIC values of >= 128 mg/L were found in all 11 non-fermentative gram-negative rods with intrinsic resistance to fosfomycin. In the combination of meropenem/colistin, synergy and partial synergy were observed in 11 (40.7%) of 27 isolates, an indifference effect was observed in 13 (48.2%), and antagonistic effects were observed in three (11.1%) of the isolates. The synergy and partial synergy effects of this combination were 37.5% for Enterobacterales group bacteria, 50% for E.coli, and 30% for K.pneumoniae. Regarding the 11 non-fermentative gram-negative rods included in the study, 83.3% synergy and partial synergy was found in A.baumannii for the meropenem/colistin combination, while no synergy and partial synergistic effect was found in P.aeruginosa. Meropenem/fosfomycin synergy and partial synergy effects were 83.3% (5/6) for E.coli, 100% (8/8) for K.pneumoniae, 100% (6/6) for A.baumannii, and 25% (1/4) for P.aeruginosa. In all of the isolates studied, meropenem/fosfomycin combination was found to be more effective than the meropenem/colistin combination. It would be meaningful to support these data obtained in vitro with clinical efficacy results to be obtained as a result of the application of antibiotics in vivo, taking into account the pharmacokinetic and pharmacodynamic properties of the antibiotics used in this study.


  • Open Access

    Can colistin susceptibility results determined in multidrug resistant Gram-negative bacteria be used for polymyxin B?

    by Rıza Adaleti, Nilgün Kansak, Şeyma Çalık, Neslihan Arıcı, Seniha Şenbayrak, Sebahat Aksaray

    Introduction: The present study aimed to compare the MIC values of colistin and polymyxin B in fermentative and non-fermentative Gram-negative bacteria and to examine whether the susceptibility results determined with colistin can be used for polymyxin B. Materials and Methods: A total of 268 strains of Escherichia coli ( E. coli ), Klebsiella pneumoniae ( K. pneumoniae ), Pseudomonas aeruginosa ( P. aeruginosa ), and Acinetobacter baumannii ( A. baumannii ) isolates were included in the study. The reference broth microdilution and the results were evaluated according to CLSI recommendations. Results: Of the 268 strains, 40.7% were found to be colistin resistant and 34% polymyxin B resistant. Essential agreement (EA) and categorical agreement (CA) ratios for all isolates were found to be 81.3% and 85.1%, respectively. Identical MIC values were found for colistin and polymyxin B in 104 isolates (38.8%), and this rate was 31.1% and 48.7% in Enterobacterales and non-fermentative bacteria, respectively. Colistin resistance rates were 25.4% for E. coli , 67.4% for K. pneumoniae , 23.8% for P. aeruginosa , and 31.5% for A. baumannii . Polymyxin B resistance rates were 18.6% for E. coli , 64.1% for K. pneumoniae , 19% for P. aeruginosa , and 16.7% for A. baumannii . Conclusion: According to the results of the study, it was concluded that the MIC values of colistin and polymyxin B antibiotics in all bacteria were not compatible with each other. Colistin susceptibility results cannot be used for treatment with polymyxin B, despite CLSI's recommendation.